Simulations Plus (SLP) announced the completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development and strengthen the scientific foundation of the industry’s future workforce. More than 1,400 scientists from industry, academia, and regulatory agencies from over 65 countries participated in the week-long program, reflecting the high demand for expert-led training as modeling and simulation increasingly become standard for drug development strategy, regulatory engagement, and clinical execution. “As model-informed approaches become central to how therapies are developed, it is vital to apply modeling and simulation consistently across teams,” said Jonathan Chauvin, Co-Chief Product and Technology Officer of Simulations Plus. “Through programs like Spring School, we are expanding access to these capabilities to support the next generation of scientists, while enabling broader adoption of model-informed workflows across the industry. These foundational skills are essential for scientists to evolve with the discipline and leverage validated scientific engines and AI-enabled ecosystems to support better decision-making across the drug development lifecycle.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump
- Morning Movers: Organon jumps after report of Sun Pharmaceutical bid
- Simulations Plus price target lowered to $16 from $19 at TD Cowen
- Simulations Plus: Solid Q2 and Long-Term Potential Tempered by EPS Headwinds and Biopharma Spending Uncertainty Supporting Hold Rating
- Closing Bell Movers: Markets on edge ahead of US-Iran talks
